Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
typhoid and paratyphoid A conjugate vaccine
- Development stage
- Preclinical
- Lead developer
- GSK
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A bivalent typhoid and paratyphoid A conjugate vaccine is an investigational vaccine designed to prevent both typhoid (caused by *Salmonella enterica* serovar Typhi) and paratyphoid A fever (caused by *Salmonella enterica* serovar Paratyphi A)[5][2][3]. These vaccines combine the Vi polysaccharide antigen from *S. Typhi* with the O:2 O-specific polysaccharide from *S. Paratyphi A*, each conjugated to protein carriers such as tetanus toxoid, diphtheria toxoid, CRM197, or recombinant bacterial proteins in order to induce a robust, T-cell–dependent immune response even in young children[2][3][5]. The mechanism of action is based on the induction of humoral immunity (IgG and IgA), complement-mediated bactericidal activity, and cell-mediated immunity via T-helper (Th1/Th17) and cytotoxic T-cell responses against both pathogens.
- Other names
- bivalent typhoid-paratyphoid A conjugate vaccinebivalent typhoid-paratyphoid conjugate vaccinetyphoid-paratyphoid A conjugate vaccinetyphoid and paratyphoid conjugate vaccine
02
Targets
LPS (Lipopolysaccharide)Vi antigen (Vi capsular polysaccharide)
Beyond the preview
Go deeper on typhoid and paratyphoid A conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on typhoid and paratyphoid A conjugate vaccine.